In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.
John R. Ferguson
Advertisement
Articles by John R. Ferguson
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
3
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
4
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
5